Advertisement

Topics

New Health Canada Licence Allows Maricann Group (CSE:MARI) (CSE:MARI.CN) (CNSX:MARI) (OTCQB:MRRCF) to Increase #Cannabis Production by Over 480% to 6,250,000 grams

01:00 EST 8 Nov 2017 | InvestorIdeas

TORONTO, ONTARIO - November 8, 2017 (Investorideas.com Newswire) Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI) (OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company"), is pleased to announce that Health Canada has granted Maricann Inc. a new licence that removes annual production limits on approved medical cannabis products in its current Langton, Ontario facility.

Original Article: New Health Canada Licence Allows Maricann Group (CSE:MARI) (CSE:MARI.CN) (CNSX:MARI) (OTCQB:MRRCF) to Increase #Cannabis Production by Over 480% to 6,250,000 grams

NEXT ARTICLE

More From BioPortfolio on "New Health Canada Licence Allows Maricann Group (CSE:MARI) (CSE:MARI.CN) (CNSX:MARI) (OTCQB:MRRCF) to Increase #Cannabis Production by Over 480% to 6,250,000 grams"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...